2027
Go

Health Care : Biotechnology | Small Cap Growth

IVERIC bio, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development ofl treatments for retinal diseases with unmet medical needs. Its lead asset clinical stage product candidate Zimura, a complement C5 inhibitor. Zimura is targeting diseases include: Geographic Atrophy (GA), intermediate (age-related macular degeneration) AMD, and autosomal recessive Stargardt disease (STGD1). It is also developing preclinical product candidate IC-500, a High temperature requirement A serine peptidase 1 protein (HtrA1) inhibitor for GA and potentially other age-related retinal diseases. Its portfolio also includes two preclinical stage gene therapy product candidates, which include IC-100 and IC-200 and several ongoing gene therapy research programs. The Company is developing IC-100 for rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP) and IC-200 for bestrophin-1 (BEST1) related IRDs.

Closing Price: $10.44

Day's Change: 0.47 (4.71%)

Bid: --

Ask: --

B/A Size: --

Day's High: 10.47

Day's Low: 9.90

Volume (Heavy Day) Volume: 6,244,975 10-day average volume: 2,697,044: 6,244,975

Ollie's Bargain Outlet started at hold with $50 stock price target at Truist

7:27 am ET January 13, 2022 (MarketWatch) Print

(END) Dow Jones Newswires

January 13, 2022 07:27 ET (12:27 GMT)

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for varies.

Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and